血管紧张素转换酶的制备与功能。
The preparation and function of the hypertensin-converting enzyme.
作者信息
SKEGGS L T, KAHN J R, SHUMWAY N P
出版信息
J Exp Med. 1956 Mar 1;103(3):295-9. doi: 10.1084/jem.103.3.295.
Abstract
It has been shown by use of isolated, perfused rat kidneys that hypertensin II is a potent vasoconstrictor substance while hypertensin I is not. Hence it would appear that in intact animals the pressor activity of hypertensin I results from its rapid conversion to hypertensin II. An enzyme which effects this conversion has been procured from horse plasma in a semipurified form by means of ammonium sulfate fractionation and isoelectric precipitation. A method is described for estimating the activity of the enzyme. An example of the use of the preparation in converting purified hypertensin I to hypertensin II has been described.
摘要
利用离体灌注大鼠肾脏的实验表明，血管紧张素II是一种强效血管收缩物质，而血管紧张素I则不是。因此，在完整动物体内，血管紧张素I的升压活性似乎源于其迅速转化为血管紧张素II。通过硫酸铵分级分离和等电沉淀法，已从马血浆中以半纯化形式获得了一种能实现这种转化的酶。本文描述了一种估算该酶活性的方法。还介绍了该制剂用于将纯化的血管紧张素I转化为血管紧张素II的一个实例。
相似文献
1
The preparation and function of the hypertensin-converting enzyme.
J Exp Med. 1956 Mar 1;103(3):295-9. doi: 10.1084/jem.103.3.295.
2
The existence of two forms of hypertensin.
J Exp Med. 1954 Mar;99(3):275-82. doi: 10.1084/jem.99.3.275.
3
The amino acid composition of hypertensin II and its biochemical relationship to hypertensin I.
J Exp Med. 1956 Aug 1;104(2):183-91. doi: 10.1084/jem.104.2.183.
4
The purification of hypertensin II.
J Exp Med. 1956 Mar 1;103(3):301-7. doi: 10.1084/jem.103.3.301.
5
The amino acid sequence of hypertensin. II.
J Exp Med. 1956 Aug 1;104(2):193-7. doi: 10.1084/jem.104.2.193.
6
Renal pressor system in hypertension; evidence for circulating hypertensin in chronic renal hypertension; nature and activity of purified hypertensin.
Circulation. 1958 Apr;17(4, Part 2):658-63. doi: 10.1161/01.cir.17.4.658.
7
The purification of hypertensin I.
J Exp Med. 1954 Oct 1;100(4):363-70. doi: 10.1084/jem.100.4.363.
8
The pressor response to hypertensin in pregnant rats.
Br J Exp Pathol. 1957 Dec;38(6):635-9.
9
The assay of hypertensin from the arterial blood of normotensive and hypertensive human beings.
J Exp Med. 1952 Jun;95(6):523-9. doi: 10.1084/jem.95.6.523.
10
The isolation and assay of hypertensin from blood.
J Exp Med. 1952 Mar;95(3):241-6. doi: 10.1084/jem.95.3.241.
引用本文的文献
1
Differential effects of deleting the angiotensin receptor AT on the whole animal response to respiratory and metabolic acidosis in mice.
Am J Physiol Regul Integr Comp Physiol. 2025 Sep 1;329(3):R441-R458. doi: 10.1152/ajpregu.00088.2025. Epub 2025 Jul 18.
2
Design of Novel Mercapto-3-phenylpropanoyl Dipeptides as Dual Angiotensin-Converting Enzyme C-Domain-Selective/Neprilysin Inhibitors.
J Med Chem. 2025 Apr 10;68(7):7720-7736. doi: 10.1021/acs.jmedchem.5c00329. Epub 2025 Apr 1.
3
The Role of Renin-Angiotensin System in Diabetic Nephropathy: An Update.
Mini Rev Med Chem. 2025;25(8):591-600. doi: 10.2174/0113895575344980250130062547.
4
Molecular dissection of the role of ACE2 in glucose homeostasis.
Physiol Rev. 2025 Jul 1;105(3):935-973. doi: 10.1152/physrev.00027.2024. Epub 2025 Feb 7.
5
Vascular Endothelium at the Molecular Level: From Fundamental Knowledge Toward Medical Implementation.
Biomedicines. 2024 Dec 24;13(1):2. doi: 10.3390/biomedicines13010002.
6
Research Progress of Food-Derived Antihypertensive Peptides in Regulating the Key Factors of the Renin-Angiotensin System.
Nutrients. 2024 Dec 29;17(1):97. doi: 10.3390/nu17010097.
7
Molecular basis of human angiotensin-1 converting enzyme inhibition by a series of diprolyl-derived compounds.
FEBS J. 2025 Mar;292(5):1141-1158. doi: 10.1111/febs.17384. Epub 2025 Jan 6.
8
Radiotracers for Molecular Imaging of Angiotensin-Converting Enzyme 2.
Int J Mol Sci. 2024 Aug 30;25(17):9419. doi: 10.3390/ijms25179419.
9
Proteomic Analysis of Human Macrophages Overexpressing Angiotensin-Converting Enzyme.
Int J Mol Sci. 2024 Jun 27;25(13):7055. doi: 10.3390/ijms25137055.
10
The ACE inhibitor captopril inhibits ACN-1 to control dauer formation and aging.
Development. 2024 Feb 1;151(3). doi: 10.1242/dev.202146. Epub 2024 Feb 12.
本文引用的文献
1
Artificial kidney; construction and operation of an improved continuous dialyzer.
Proc Soc Exp Biol Med. 1949 Dec;72(3):539-43. doi: 10.3181/00379727-72-17491.
2
Amino acid composition and electrophoretic properties of hypertensin I.
J Exp Med. 1955 Oct 1;102(4):435-40. doi: 10.1084/jem.102.4.435.
3
A modified ninhydrin reagent for the photometric determination of amino acids and related compounds.
J Biol Chem. 1954 Dec;211(2):907-13.
4
The purification of hypertensin I.
J Exp Med. 1954 Oct 1;100(4):363-70. doi: 10.1084/jem.100.4.363.
5
The existence of two forms of hypertensin.
J Exp Med. 1954 Mar;99(3):275-82. doi: 10.1084/jem.99.3.275.
6
A method of assaying small amounts of hypertensin.
Lab Invest. 1953 Mar-Apr;2(2):109-14.
Zotero 插件